Convenient & effective symptom control

Convenient & effective symptom control

We need to manage allergic rhinitis as effectively as we can. Dymista® provides rapid symptom relief across the entire rhinitis spectrum1, allowing the patient to continue with everyday life.

Real life symptom control

The efficacy of Dymista® has been confirmed in a real life study1

In real life, Dymista® reduced the VAS score from 75.4mm at baseline to 21.3mm by the last visits, a shift of 54.1 mm. One in every two patients felt their symptoms were well controlled at day 4 2

chart
Click to download full slide deck

Further Your Understanding

Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.

  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
    Onset
  • Impact
    Treatment
  • Guidelines
    Guidelines
  • Clinical Papers
    Clinical Papers

References

  1. Scadding GK, e1 al, BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007) Cin Exp Allergy 2017; 47 (7) 856-889
  2. Klimek L et at Effectiveness of MP29-02 For the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy Asthma Proc 2015;36:40-47.

Want to expand your knowledge…

Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.

Viatris Connect

Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk


This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.​

Copyright © 2023 Viatris Inc All rights reserved. Dymista® is a registered trademark of Viatris Inc.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo